July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Gilberto Lopes Highlights Key Insights from Lung Oral Session at ASCO25
Jun 2, 2025, 17:43

Gilberto Lopes Highlights Key Insights from Lung Oral Session at ASCO25

Gilberto Lopes, Medical Director for International Programs and Associate Director at the Sylvester Comprehensive Cancer Center at University of Miami, shared a post on X:

“And of course: Lung Oral session
My take so far:
  • Krystal 7 IO + adagrasib is interesting as it was tolerated, but efficacy does not seem to be better than with IO alone or with chemo. Will need to wait for and see randomized trial
  • Dato shows interesting first line data with IO
  • Zipalertinib clearly active in EGFR ex20 (even after Ami)
  • BAY 2927088 shows very promising activity in people with lung cancer and HER2 mutations
  • Savolitinib + Osi have better PFS than chemo after EGFR TKIs 1st-3rd gen) and with MET amp – new option?
  • Patri improved PFS marginally and is unlikely to dethrone platinum chemo after 3rd gen TKI alone
  • Sacituzumab improves RR, PFS, and OS v docetaxel after EGFR TKI and platinum chemo and is likely to become a preferred option”

Gilberto Lopes Highlights Key Insights from Lung Oral Session at ASCO25

More posts featuring Gilberto Lopes.